METOPROLOL TARTRATE INJECTION USP SOLUTION

Држава: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

METOPROLOL TARTRATE

Доступно од:

SANDOZ CANADA INCORPORATED

АТЦ код:

C07AB02

INN (Међународно име):

METOPROLOL

Дозирање:

1MG

Фармацеутски облик:

SOLUTION

Састав:

METOPROLOL TARTRATE 1MG

Пут администрације:

INTRAVENOUS

Јединице у пакету:

5ML

Тип рецептора:

Prescription

Терапеутска област:

BETA-ADRENERGIC BLOCKING AGENTS

Резиме производа:

Active ingredient group (AIG) number: 0111923004; AHFS:

Статус ауторизације:

APPROVED

Датум одобрења:

2005-09-02

Карактеристике производа

_Metoprolol Tartrate Injection USP _
_ _
_Page 1 of 39_
PRODUCT MONOGRAPH
INCLUDING CONSUMER INFORMATION
PR
METOPROLOL TARTRATE INJECTION USP
(metoprolol tartrate)
5 mL vials (1 mg/mL)
β-Adrenergic Receptor Blocking Agent
Sandoz Canada Inc.
Date of Revision: August 10, 2020
110 Rue de Lauzon
Boucherville, QC, Canada
J4B 1E6
Submission Control No: 240543
_Metoprolol Tartrate Injection USP _
_ _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
3
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
10
DOSAGE AND ADMINISTRATION
.....................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
21
STORAGE AND STABILITY
.................................................................................................
25
SPECIAL HANDLING INSTRUCTIONS
...............................................................................
25
DOSAGE FORMS, COMPOSITION AND
PACKAGING..................................................... 25
PART II: SCIENTIFIC INFORMATION
...............................................................................
26
PHARMACEUTICAL INFORMATION
.................................................................................
26
DETAILED PHARMACOLOGY
............................................................................................
27
TOXICOLOGY...........